144 related articles for article (PubMed ID: 38330100)
1. A Metabolic-Epigenetic Mechanism Directs Cell Fate and Therapeutic Sensitivity in Breast Cancer.
Bernard MJ; Goldstein AS
Cancer Res; 2024 May; 84(9):1382-1383. PubMed ID: 38330100
[TBL] [Abstract][Full Text] [Related]
2. Metabolic switch regulates lineage plasticity and induces synthetic lethality in triple-negative breast cancer.
Zhang Y; Wu MJ; Lu WC; Li YC; Chang CJ; Yang JY
Cell Metab; 2024 Jan; 36(1):193-208.e8. PubMed ID: 38171333
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.
Yomtoubian S; Lee SB; Verma A; Izzo F; Markowitz G; Choi H; Cerchietti L; Vahdat L; Brown KA; Andreopoulou E; Elemento O; Chang J; Inghirami G; Gao D; Ryu S; Mittal V
Cell Rep; 2020 Jan; 30(3):755-770.e6. PubMed ID: 31968251
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
[TBL] [Abstract][Full Text] [Related]
6. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
Nie L; Wei Y; Zhang F; Hsu YH; Chan LC; Xia W; Ke B; Zhu C; Deng R; Tang J; Yao J; Chu YY; Zhao X; Han Y; Hou J; Huo L; Ko HW; Lin WC; Yamaguchi H; Hsu JM; Yang Y; Pan DN; Hsu JL; Kleer CG; Davidson NE; Hortobagyi GN; Hung MC
Nat Commun; 2019 Nov; 10(1):5114. PubMed ID: 31704972
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer.
Deblois G; Tonekaboni SAM; Grillo G; Martinez C; Kao YI; Tai F; Ettayebi I; Fortier AM; Savage P; Fedor AN; Liu X; Guilhamon P; Lima-Fernandes E; Murison A; Kuasne H; Ba-Alawi W; Cescon DW; Arrowsmith CH; De Carvalho DD; Haibe-Kains B; Locasale JW; Park M; Lupien M
Cancer Discov; 2020 Sep; 10(9):1312-1329. PubMed ID: 32546577
[TBL] [Abstract][Full Text] [Related]
8. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
[TBL] [Abstract][Full Text] [Related]
9. The frequency of CpG and non-CpG methylation of Notch3 gene promoter determines its expression levels in breast cancer cells.
Xiao W; Liu X; Niu X; Li C; Guo Y; Tan J; Xiong W; Fan L; Li Y
Exp Cell Res; 2020 Jan; 386(2):111743. PubMed ID: 31770532
[TBL] [Abstract][Full Text] [Related]
10. Functional relationship of SNP (Ala490Thr) of an epigenetic gene
Gautam N; Verma H; Choudhary S; Kaur S; Silakari O
J Genet; 2021; 100():. PubMed ID: 34825659
[No Abstract] [Full Text] [Related]
11. EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in triple negative breast cancer.
Wu Q; Chen Z; Zhang G; Zhou W; Peng Y; Liu R; Chen C; Feng J
Acta Biochim Biophys Sin (Shanghai); 2018 Jul; 50(7):693-700. PubMed ID: 29790898
[TBL] [Abstract][Full Text] [Related]
12. Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.
Zhang T; Gong Y; Meng H; Li C; Xue L
Clin Epigenetics; 2020 May; 12(1):72. PubMed ID: 32448308
[TBL] [Abstract][Full Text] [Related]
13. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer.
Chandnani N; Gupta I; Thakkar V; Sarkar K
Pathol Res Pract; 2023 Nov; 251():154885. PubMed ID: 37862922
[TBL] [Abstract][Full Text] [Related]
15. Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells.
Jiang F; Li Y; Si L; Zhang Z; Li Z
Cell Biol Toxicol; 2019 Aug; 35(4):361-371. PubMed ID: 30612216
[TBL] [Abstract][Full Text] [Related]
16. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-activated XBP1s recruits HDAC2-EZH2 to engage epigenetic suppression of ΔNp63α expression and promote breast cancer metastasis independent of HIF1α.
Chen H; Yu S; Ma R; Deng L; Yi Y; Niu M; Xu C; Xiao ZJ
Cell Death Differ; 2024 Apr; 31(4):447-459. PubMed ID: 38413797
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
20. Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas.
Vinchure OS; Sharma V; Tabasum S; Ghosh S; Singh RP; Sarkar C; Kulshreshtha R
Int J Cancer; 2019 Sep; 145(5):1254-1269. PubMed ID: 31008529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]